期刊文献+

Ⅵ型胶原蛋白相关肌病的临床特点与致病基因分析 被引量:8

Clinical manifestations and gene diagnosis of collagen type VI related myopathy
原文传递
导出
摘要 目的总结Ⅵ型胶原蛋白相关肌病的临床表现、辅助检查结果和基因诊断,更好地识别和诊断这类少见遗传性肌病。方法对7例基因确诊的家族型或散发型Ⅵ型胶原蛋白相关肌病患者进行回顾性临床研究,总结其症状体征、肌酶谱、肌电图、肌肉MRI、肌肉活体组织检查(简称活检)病理以及基因型与表现型相关性等方面特点。结果7例患者中以COL6A1、COL6A2、COL6A3为致病基因的分别为3例、1例和3例。2例为家族型,5例为散发型。下肢为重的肢体近端无力、关节挛缩为主要临床表现。血肌酸激酶轻微升高。肌电图提示轻度肌源性损害。大腿肌肉MRI示特征性分布肌群受累。肌肉活检病理可见肌营养不良样改变,多数肌纤维结构清楚,肌纤维问胶原结缔组织增牛。结论对于渐进性肌肉无力伴早发关节挛缩,肌酸激酶轻度升高,下肢肌肉MRI呈选择性受累的患者,应注意Ⅵ型胶原蛋白相关肌病可能。临床工作中注意识别Ⅵ型胶原蛋白相关肌病临床特点,对疑诊患者进行高通量测序基因诊断,有助于提高诊断率。 Objective To summarize the clinical presentations, the findings of lab tests and procedures and the genetic investigation of collagen type VI related myopathy, and to help clinicians recognize and diagnose this rare disease. Methods Seven familiar or spontaneous collagen type VI related myopathy patients diagnosed by gene detection were analyzed. We emphasized on the features of clinical manifestations, serum creatine kinase level, eleetromyography, lower-limb muscle MRI, muscle biopsy and correlation between genotype and phenotype. Results Among 7 patients, 3 were caused by COL6AI mutation, 1 was caused by COL6A2 mutation and 3 were caused by COL6A3 mutation. Two patients were familiar while 5 were spontaneous. Highlighted clinical presentations were proximal weakness in lower limbs and joint contrature. Serum creatine kinase level was slightly elevated. Electromyography showed slight myogenic damage. Muscle MRI of thigh showed distinct pattern of muscle involvement. Muscle pathology revealed dystrophic myogenic changes with proliferation of connective tissue between muscle fibers. Conclusions Neurologists should recognize the features of collagen type gl related myopathy, such as progressive weakness, early-onset joint contractures, slightly elevated serum creatine kinase and selective muscle involvement on leg MRI scan, and then perform next-generation sequencing based genetic test on suspected patients. This approach would improve the diagnostic rate of the disease.
出处 《中华神经科杂志》 CAS CSCD 北大核心 2015年第11期974-979,共6页 Chinese Journal of Neurology
关键词 胶原Ⅵ型 肌疾病 关节挛缩 肌营养不良 高通量核苷酸序列分析 Collagen type gl Muscular diseases Arthrogryposis Muscular dystrophies High-throughput nucleotide sequencing
  • 相关文献

参考文献14

  • 1Hessle H, Engvall E. Type VI collagen. Studies on its localization, structure and biosynthetic form with monoclonal antibodies[J]. J Biol Chem, 1984, 259(6) : 3955-3961.
  • 2Heiskanen M, Saitta B, Palotie A, et al. Head to tail organization of the human COL6A1 and COL6A2 genes by fiber-FISH [ J]. Genomics, 1995, 29(3 ) : 801-803.
  • 3Weil D, Mattei MG, Passage E, et al. Cloning and chromosomal localization of human genes encoding the three chains of type V[ collagen[ J ]. Am J Hum Genet, 1988,42 (3) : 435-445.
  • 4Merlini L, Martoni E, Grumati P, et al. Autosomal recessive myoselerosis myopathy is a collagen WI disorder [ J]. Neurology, 2008, 71(16) : 1245-1253.
  • 5Scacheri PC, Gillanders EM, Subramony SH, et al. Novel mutations in collagen WI genes: expansion of the Bethlem myopathy phenotype [ J]. Neurology, 2002, 58 (4) : 593-602.
  • 6戴毅,姚凤霞,魏晓明,孙岩,任海涛,赵燕环,陈琳,崔丽英.基因芯片捕获及高通量测序在迪谢内型肌营养不良基因诊断中的初步研究[J].中华神经科杂志,2013,46(3):188-192. 被引量:10
  • 7Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-423.
  • 8Mohire MD, Tandan R, Fries TJ, et al. Early-onset benign autosomal dominant limb-girdle myopathy with contractures ( Bethlem myopathy) [ J]. Neurology, 1988, 38 (4) : 573-580.
  • 9Jobsis GJ, Boers JM, Barth PG, et al. Bethlem myopathy: aslowly progressive congenital muscular dystrophy with contractures [J]. Brain, 1999, 122(4): 649-655.
  • 10Mercuri E, Lampe A, Allsop J, et al. Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy [ J ]. Neuromuscul Disord, 2005, 15 (4) : 303-310.

二级参考文献16

  • 1Bushby K, Finkel R, Birnkrant D J, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1 : diagnosis, and pharmacological and psychosocial management. Lancet Neurol, 2010, 9: 77-93.
  • 2Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 1987, 51 : 919-928.
  • 3Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol, 2003, 2 : 731-740.
  • 4Aartsma-Rus A, Van Deutekom JC, Fokkema IF, et al. Entries in the Leiden Duchenne muscular dystrophy mutation database : an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve, 2006, 34 : 135-144.
  • 5Jennekens FG, ten Kate LP, de Visser M, et al. Diagnostic criteria for Duchenne and Becker muscular dystrophy and myotonic dystrophy. Neuromuscul Disord, 1991, 1: 389-391.
  • 6Wei X, Ju X, Yi X, et al. Identification of sequence variants in genetic disease-causing genes using targeted next-generation sequencing. PLoS One, 2011, 6: e29500.
  • 7Bushby K, Finkel R, Birnkrant D J, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidiseiplinary care. Lancet Neurol, 2010, 9 : 177-189.
  • 8Malik V, Rodino-Klapac LR, Viollet L, et al. Gentamicin- induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol, 2010, 67: 771-780.
  • 9Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature, 2007, 447 : 87- 91.
  • 10Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne' s muscular dystrophy. N Engl J Med, 2011, 364: 1513-1522.

共引文献9

同被引文献21

  • 1Chaouch A, Muller JS, Guerguehcheva V, et al. A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome[ J ]. J Neurol, 2012, 259 ( 3 ) : 474-481. DOI : 10. 1007/s04154311-6204-9.
  • 2Muller JS, Herczegfalvi A, Vilchez JJ, et al. Phenntypical spectru of DOK7 mutations in conngenital myasthenic syndromes [J]. Brain, 2007, 130(Pt6): 1497-1506.
  • 3Ohno K, Brengman J, Tsujino A, et al. Humao endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme [ J ]. Proc Natl Acad Sci U S A, 1998, 95(16) : 9654-9659.
  • 4Mihaylova V, Mailer JS, Vilchez JJ, et al. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes [J]. Brain, 2008, 131(Pt3): 747-759. DOI: 10. 1093/brain/ awnd25.
  • 5Gandolfi B, Grahn RA, Creighton EK, et al. COLQ variant associated with Devon Rex and Sphynx feline hereditary myopathy [J]. Anim Genet, 2015, 46(6): 711-715. DOI: 10.1111/ age. 12350.
  • 6Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology [ J ]. Genet Med, 2015, 17(5) : 405-424. DOI: 10. 1038/gim. 2015.30.
  • 7Kimbell LM, Ohno K, Engel AG, et al. C-terminal and heparin- binding domains of collagenic tail subunit are both essential for anchoring acetyleholinesterase at the synapse [J].J Biol Chem, 2004, 279 (12) : 10997-11005.
  • 8Beeson D, HantaY D, Lochmliller H, et al. 126th International Workshop: congenital myasthenic syndromes, 24-26 September 2004, Naarden, the Netherlands [ J ] . Neuromuseul Disord,2005, 15(7) : 498-512.
  • 9Kohara N, Lin TS, Fukudonae T, et al. Pathophysiology of weakness in a patient with congenital end-plate acetyleholinesterase defieiency[J]. Muscle Nerve, 2002, 25 (4) : 585-592.
  • 10Engel AG. The therapy of congenital myasthenic syndromes [ J ]. Neurotherapeutics, 2007, 4 (2) : 252-257.

引证文献8

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部